More recently, we and others have provided evidence that ADCs targeting HER‐3 possess potent and specific activity in metastatic melanoma as well as EGFR inhibitor‐resistant lung carcinoma, pancreatic, and colorectal carcinoma (Capone et al, 2018; Bourillon et al, 2019; Hashimoto et al, 2019; Koganemaru et al, 2019; Yonesaka et al, 2019; Haratani et al, 2020). This evidence concerns the gene EGFR and lung carcinoma.